Recently, Coris Medical, China’s innovative vascular interventional platform, announced the completion of a Series C financing round worth several hundred million RMB, jointly led by Hillhouse Ventures and YuanSheng Venture Capital. The proceeds will be primarily used for advancing clinical development of tumor interventional products, registering multiple pipeline products currently in development, continuing R&D on subsequent pipeline programs, as well as brand marketing and channel building.

Founded at the end of 2015, Coris Medical is a platform company focusing on the R&D, manufacture, sales, and service of vascular interventional medical devices. Headquartered in Shenzhen, it operates two distinctive technology platforms and has GMP‑certified Class 10,000 cleanroom production facilities in both Shenzhen and Beijing. Its product portfolio spans three major fields: tumor intervention, vascular access, and cardiovascular intervention.

The founding team consists of clinical physicians and elite medical device R&D experts. Driven by “therapy insight,”they seamlessly bridge technical engineering language with clinical needs, aiming to develop and produce vascular interventional devices better suited to Chinese patients, alleviating suffering and extending lives. As a results‑oriented “fast fish” team, the company obtained five Class III medical device registration certificates within five years of its establishment.

Beijing Caihe Law Firm conducted Freedom‑to‑Operate (FTO) due diligence for patent infringement risks in this financing round.